
BridgeBio Pharma BBIO is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here’s a quick overview of what investors should know before the release.
Analysts are estimating that BridgeBio Pharma will report an earnings per share (EPS) of $-0.86.
Investors in BridgeBio Pharma are eagerly awaiting the company’s announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It’s worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Earnings Track Record
Last quarter the company missed EPS by $0.31, which was followed by a 0.12% increase in the share price the next day.
Here’s a look at BridgeBio Pharma’s past performance and the resulting price change:
Quarter | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
---|---|---|---|---|
EPS Estimate | -1.09 | -0.98 | -1.04 | -0.89 |
EPS Actual | -1.40 | -0.86 | -1.06 | -0.20 |
Price Change % | 0.0% | 1.0% | 0.0% | 0.0% |
BridgeBio Pharma Share Price Analysis
Shares of BridgeBio Pharma were trading at $36.305 as of April 25. Over the last 52-week period, shares are up 37.82%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for BridgeBio Pharma visit their earnings calendar on our site.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.